GlassScriptPhysician profile
Brady Simonak
NPI 1821418658
$9,910.87
in general payments reported to CMS, 2019-2025
61 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $1,301 · 2021: $1,529 · 2022: $1,626 · 2023: $1,549 · 2024: $1,644 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,501.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,272.15 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $800.70 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $713.02 | 2019-2025 | Jardiance |
| Abbott Laboratories | $681.76 | 2022-2025 | Freestyle Libre, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $657.49 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $598.29 | 2019-2024 | Cycloset, Xifaxan |
| Pfizer INC. | $575.20 | 2019-2025 | |
| Glaxosmithkline, LLC. | $467.35 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $392.84 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $354.70 | 2022-2025 | |
| Allergan, INC. | $311.11 | 2019-2020 | |
| Amgen INC. | $300.45 | 2019-2025 | Repatha, Otezla, Otezla |
| Kowa Pharmaceuticals America, INC. | $213.78 | 2019-2024 | Livalo |
| Amarin Pharma, INC. | $173.20 | 2019-2022 | |
| Avvisto Therapeutics, LLC | $159.60 | 2024-2025 | Cycloset |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brady Simonak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.